Blueprint Medicines
Blueprint Medicines Corporation, headquartered in the United States, is a leading player in the pharmaceutical preparation manufacturing industry. Founded in 2008, the company has made significant strides in developing targeted therapies for genomically defined cancers, rare diseases, and cancer immunotherapy.
With a focus on precision medicine, Blueprint Medicines offers a unique portfolio of innovative products, including targeted therapies that address specific genetic mutations. Their commitment to advancing treatment options has positioned them as a key competitor in the oncology market.
Notable achievements include the successful launch of several breakthrough therapies, which have garnered attention for their efficacy and safety profiles. As a pioneer in the field, Blueprint Medicines continues to push the boundaries of science, striving to improve patient outcomes and redefine treatment paradigms.
+22 vs industry average
Blueprint Medicines’s score of 62 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Blueprint Medicines?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Blueprint Medicines's reported carbon emissions
Blueprint Medicines, a pharmaceutical preparation manufacturing company based in the US, reported a total of approximately 1.02 million kg CO2e for Scope 1 and Scope 2 emissions in 2024. This figure includes market-based Scope 1 emissions of about 208,180 kg CO2e and market-based Scope 2 emissions of approximately 819,840 kg CO2e. The company's reporting for 2024 does not include Scope 3 emissions data, with a specific mention of missing data points for purchased goods and services.
Blueprint Medicines's emissions data is cascaded from its parent organisation, Blueprint Medicines Corporation, which in turn inherits targets from Sanofi for initiatives like the Science Based Targets initiative (SBTi), RE100, and the Race to Zero (RTZ). Specific reduction targets for Blueprint Medicines are not detailed in the provided information.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Blueprint Medicines’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Blueprint Medicines yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Blueprint Medicines
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project